1.Lam KO, Lee AW, Choi CW, Sze HC, Zietman AL, Hopkins KI, Rosenblatt E: Global Pattern of Nasopharyngeal Cancer: Correlation of Outcome With Access to Radiation Therapy. International journal of radiation oncology, biology, physics 2016, 94(5):1106–1112.
2.Wei KR, Zheng RS, Zhang SW, Liang ZH, Li ZM, Chen WQ: Nasopharyngeal carcinoma incidence and mortality in China, 2013. Chin J Cancer 2017, 36(1):90.
3.Lee AW, Ng WT, Chan LL, Hung WM, Chan CC, Sze HC, Chan OS, Chang AT, Yeung RM: Evolution of treatment for nasopharyngeal cancer—success and setback in the intensity-modulated radiotherapy era. Radiotherapy and oncology: journal of the European Society for Therapeutic Radiology and Oncology 2014, 110(3):377–384.
4.Al-Sarraf M, LeBlanc M, Giri PG, Fu KK, Cooper J, Vuong T, Forastiere AA, Adams G, Sakr WA, Schuller DE et al: Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099. Journal of clinical oncology: official journal of the American Society of Clinical Oncology 1998, 16(4):1310–1317.
5.Lee AW, Tung SY, Ngan RK, Chappell R, Chua DT, Lu TX, Siu L, Tan T, Chan LK, Ng WT et al: Factors contributing to the efficacy of concurrent-adjuvant chemotherapy for locoregionally advanced nasopharyngeal carcinoma: combined analyses of NPC–9901 and NPC–9902 Trials. European journal of cancer (Oxford, England: 1990) 2011, 47(5):656–666.
6.Wang J, Chen YY, Tai A, Chen XL, Huang SM, Yang C, Bao Y, Li NW, Deng XW, Zhao C et al: Sensorineural Hearing Loss after Combined Intensity Modulated Radiation Therapy and Cisplatin-Based Chemotherapy for Nasopharyngeal Carcinoma. Translational oncology 2015, 8(6):456–462.
7.Zeng L, Tian YM, Sun XM, Chen CY, Han F, Xiao WW, Deng XW, Lu TX: Late toxicities after intensity-modulated radiotherapy for nasopharyngeal carcinoma: patient and treatment-related risk factors. British journal of cancer 2014, 110(1):49–54.
8.Strojan P, Vermorken JB, Beitler JJ, Saba NF, Haigentz M, Jr., Bossi P, Worden FP, Langendijk JA, Eisbruch A, Mendenhall WM et al: Cumulative cisplatin dose in concurrent chemoradiotherapy for head and neck cancer: A systematic review. Head & neck 2016, 38 Suppl 1:E2151–2158.
9.Ang KK: Concurrent radiation chemotherapy for locally advanced head and neck carcinoma: are we addressing burning subjects? Journal of clinical oncology: official journal of the American Society of Clinical Oncology 2004, 22(23):4657–4659.
10.Al-Mamgani A, de Ridder M, Navran A, Klop WM, de Boer JP, Tesselaar ME: The impact of cumulative dose of cisplatin on outcome of patients with head and neck squamous cell carcinoma. European archives of oto-rhino-laryngology: official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS): affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery 2017, 274(10):3757–3765.
11.Wei W, Huang Z, Li S, Chen H, Zhang G, Li S, Hu W, Xu T: Pretreatment Epstein-Barr virus DNA load and cumulative cisplatin dose intensity affect long-term outcome of nasopharyngeal carcinoma treated with concurrent chemotherapy: experience of an institute in an endemic area. Oncology research and treatment 2014, 37(3):88–95.
12.Peng H, Chen L, Zhang Y, Li WF, Mao YP, Zhang F, Guo R, Liu LZ, Lin AH, Sun Y et al: Prognostic Value of the Cumulative Cisplatin Dose During Concurrent Chemoradiotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma: A Secondary Analysis of a Prospective Phase III Clinical Trial. The oncologist 2016.
13.Guo SS, Tang LQ, Zhang L, Chen QY, Liu LT, Guo L, Mo HY, Luo DH, Huang PY, Xiang YQ et al: The impact of the cumulative dose of cisplatin during concurrent chemoradiotherapy on the clinical outcomes of patients with advanced-stage nasopharyngeal carcinoma in an era of intensity-modulated radiotherapy. BMC cancer 2015, 15:977.
14.Loong HH, Ma BB, Leung SF, Mo F, Hui EP, Kam MK, Chan SL, Yu BK, Chan AT: Prognostic significance of the total dose of cisplatin administered during concurrent chemoradiotherapy in patients with locoregionally advanced nasopharyngeal carcinoma. Radiotherapy and oncology: journal of the European Society for Therapeutic Radiology and Oncology 2012, 104(3):300–304.
15.Ou X, Xu T, He X, Ying H, Hu C: Who benefited most from higher cumulative dose of cisplatin among patients with locally advanced nasopharyngeal carcinoma treated by intensity-modulated radiation therapy? A retrospective study of 527 cases. Journal of Cancer 2017, 8(14):2836–2845.
16.Peng H, Chen L, Li WF, Guo R, Mao YP, Zhang Y, Zhang F, Liu LZ, Tian L, Lin AH et al: The Cumulative Cisplatin Dose Affects the Long-Term Survival Outcomes of Patients with Nasopharyngeal Carcinoma Receiving Concurrent Chemoradiotherapy. Scientific reports 2016, 6:24332.
17.Zhang B, Mo Z, Du W, Wang Y, Liu L, Wei Y: Intensity-modulated radiation therapy versus 2D-RT or 3D-CRT for the treatment of nasopharyngeal carcinoma: A systematic review and meta-analysis. Oral Oncol 2015, 51(11):1041–1046.
18.Peng G, Wang T, Yang KY, Zhang S, Zhang T, Li Q, Han J, Wu G: A prospective, randomized study comparing outcomes and toxicities of intensity-modulated radiotherapy vs. conventional two-dimensional radiotherapy for the treatment of nasopharyngeal carcinoma. Radiotherapy and oncology: journal of the European Society for Therapeutic Radiology and Oncology 2012, 104(3):286–293.
19.Chen YP, Wang ZX, Chen L, Liu X, Tang LL, Mao YP, Li WF, Lin AH, Sun Y, Ma J: A Bayesian network meta-analysis comparing concurrent chemoradiotherapy followed by adjuvant chemotherapy, concurrent chemoradiotherapy alone and radiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma. Annals of oncology: official journal of the European Society for Medical Oncology 2015, 26(1):205–211.
20.Yan M, Kumachev A, Siu LL, Chan KK: Chemoradiotherapy regimens for locoregionally advanced nasopharyngeal carcinoma: A Bayesian network meta-analysis. European journal of cancer (Oxford, England: 1990) 2015, 51(12):1570–1579.
21.Ribassin-Majed L, Marguet S, Lee AWM, Ng WT, Ma J, Chan ATC, Huang PY, Zhu G, Chua DTT, Chen Y et al: What Is the Best Treatment of Locally Advanced Nasopharyngeal Carcinoma? An Individual Patient Data Network Meta-Analysis. Journal of clinical oncology: official journal of the American Society of Clinical Oncology 2017, 35(5):498–505.
22.Zhong Q, Zhu X, Li L, Qu S, Liang Z, Zeng F, Pan X: IMRT combined with concurrent chemotherapy plus adjuvant chemotherapy versus IMRT combined with concurrent chemotherapy alone in patients with nasopharyngeal carcinoma. Oncotarget 2017, 8(24):39683–39694.